RAS pathway mutations (NRAS, KRAS, PTPN11, and CBL) were present in 27.0% (20 of 74) of patients and mainly occurred in KMT2A-rearranged cases and CN-AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.